Risopet 150 mg , 75 mg , 400 mg and 275 mg FC tablets
PDF Leaflet Revision Date: 15 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Initial phase treatment of pulmonary and extra-pulmonary tuberculosis.
Dosage (summary)
Adults: 2-5 tablets daily based on body weight.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Not established; may cause post-natal hemorrhages. Excreted in breast milk.
Key Drug Interactions
- Antacids reduce bioavailability
- Rifampicin induces CYP450 enzymes
- Isoniazid may increase warfarin levels
Contraindications
- Hypersensitivity to components
- Active hepatic disease
- Severe renal impairment
- Optic neuritis
- Pregnancy and lactation
- Children under 13 years
Common side effects
- Nausea
- Vomiting
- Dizziness
- Visual disturbances
- Hepatotoxicity
Counselling Points
- Take with a full glass of water
- Avoid soft contact lenses
- Report any signs of liver dysfunction or severe skin reactions
Serious warnings
- Risk of severe liver dysfunction
- Monitor for hypersensitivity reactions
- Potential for serious skin reactions
Important Disclaimer
The Risopet 150 mg , 75 mg , 400 mg and 275 mg FC tablets professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
